Overview Dividends

(PRGO) Perrigo - Ratings and Ratios

Exchange: NYSE • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00BGH1M568

OTC, Vitamins, Infant Formula, Skin Care, Oral Care

EPS (Earnings per Share)

EPS Growth (3y CAGR): 2.37%
EPS Trend (3y Corr): 0.2%

Last SUE: 0.18σ
Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): -3.64%
Revenue Trend (3y Corr): -83.0%

Last SUE: -2.23σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	35.4%
Value at Risk 5%th	50.0%
Relative Tail Risk	-14.20%

Reward TTM
Sharpe Ratio	-1.56
Alpha	-62.11

Character TTM
Hurst Exponent	0.498
Beta	0.681
Beta Downside	0.769

Drawdowns 3y
Max DD	66.45%
Mean DD	22.92%
Median DD	25.41%

Description: PRGO Perrigo November 08, 2025

Perrigo Company plc (NYSE: PRGO) is a Dublin-based manufacturer of over-the-counter (OTC) health and wellness products, operating through Consumer Self-Care Americas and Consumer Self-Care International segments. Its portfolio spans upper-respiratory remedies, infant nutrition, digestive health, pain and sleep aids, oral-care accessories, smoking-cessation tools, skin-care treatments, women’s health items, vitamins, and a niche rare-disease business, sold under brands such as Good Sense, Mederma, Plackers, NiQuitin, and ellaOne.

The company reaches consumers via drug-store chains, supermarkets, mass-merchandise retailers, e-commerce platforms, wholesalers, and para-pharmacies, and also provides contract-manufacturing services to third-party brands. In FY 2023 Perrigo reported roughly $2.5 billion in net sales, with a gross margin of about 38 % and an operating cash flow of $310 million, reflecting the relatively low-cost structure of generic OTC production. Key sector drivers include steady U.S. OTC demand (estimated at $35 billion annually), price-inflation pressure on raw materials, and a consumer shift toward online purchasing, which grew ~12 % YoY in 2023.

Given the modest growth outlook for generic OTC volumes and the company’s exposure to currency fluctuations (Euro-dollar), analysts should monitor the pace of new product launches and the impact of supply-chain constraints on cost of goods sold. For a deeper, data-driven look at Perrigo’s valuation and peer benchmarks, the ValueRay platform provides a concise dashboard that can help inform your next research step.

PRGO Stock Overview

Market Cap in USD	1,923m
Sub-Industry	Pharmaceuticals
IPO / Inception	1991-12-16
Return 12m vs S&P 500	-57.9%
Analyst Rating	3.80 of 5

PRGO Dividends

Metric	Value
Dividend Yield	9.35%
Yield on Cost 5y	2.82%
Yield CAGR 5y	5.24%
Payout Consistency	100.0%
Payout Ratio	49.8%

PRGO Growth Ratios

Metric	Value
CAGR 3y	-25.52%
CAGR/Max DD Calmar Ratio	-0.38
CAGR/Mean DD Pain Ratio	-1.11
Current Volume	4049.6k
Average Volume	3637k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-51.8m TTM) > 0 and > 6% of Revenue (6% = 256.9m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA 1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 40.49% (prev 51.40%; Δ -10.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 375.7m > Net Income -51.8m (YES >=105%, WARN >=100%)

Net Debt (3.39b) to EBITDA (611.5m) ratio: 5.55 <= 3.0 (WARN <= 3.5)

Current Ratio 2.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (138.9m) change vs 12m ago 1.02% (target <= -2.0% for YES)

Gross Margin 35.46% (prev 36.07%; Δ -0.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 40.23% (prev 39.20%; Δ 1.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.59 (EBITDA TTM 611.5m / Interest Expense TTM 175.7m) >= 6 (WARN >= 3)

Altman Z'' 1.40

(A) 0.17 = (Total Current Assets 2.88b - Total Current Liabilities 1.15b) / Total Assets 10.08b

(B) -0.22 = Retained Earnings (Balance) -2.26b / Total Assets 10.08b

(D) 0.79 = Book Value of Equity 4.45b / Total Liabilities 5.64b

Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.10

1. Piotroski 3.50pt

2. FCF Yield 5.10%

3. FCF Margin 6.34%

4. Debt/Equity 0.86

5. Debt/Ebitda 5.55

6. ROIC - WACC (= -1.41)%

7. RoE -1.18%

8. Rev. Trend -83.01%

9. EPS Trend 0.16%

What is the price of PRGO shares?

As of November 21, 2025, the stock is trading at USD 12.26 with a total of 4,049,577 shares traded.
Over the past week, the price has changed by -12.24%, over one month by -43.50%, over three months by -47.54% and over the past year by -52.87%.

Is PRGO a buy, sell or hold?

Perrigo has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold PRGO.

Strong Buy: 1
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PRGO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21.5	75.4%
Analysts Target Price	21.5	75.4%
ValueRay Target Price	10.5	-14.4%

PRGO Fundamental Data Overview November 15, 2025

Market Cap USD = 1.92b (1.92b USD * 1.0 USD.USD)
P/E Forward = 4.8662
P/S = 0.449
P/B = 0.4383
P/EG = 1.1418
Beta = 0.357
Revenue TTM = 4.28b USD
EBIT TTM = 279.6m USD
EBITDA TTM = 611.5m USD
Long Term Debt = 3.61b USD (from longTermDebt, last quarter)
Short Term Debt = 65.0m USD (from shortTermDebt, last quarter)
Debt = 3.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.39b USD (from netDebt column, last quarter)
Enterprise Value = 5.32b USD (1.92b + Debt 3.83b - CCE 432.1m)
Interest Coverage Ratio = 1.59 (Ebit TTM 279.6m / Interest Expense TTM 175.7m)
FCF Yield = 5.10% (FCF TTM 271.4m / Enterprise Value 5.32b)
FCF Margin = 6.34% (FCF TTM 271.4m / Revenue TTM 4.28b)
Net Margin = -1.21% (Net Income TTM -51.8m / Revenue TTM 4.28b)
Gross Margin = 35.46% ((Revenue TTM 4.28b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 36.14% (prev 34.36%)
Tobins Q-Ratio = 0.53 (Enterprise Value 5.32b / Total Assets 10.08b)
Interest Expense / Debt = 1.41% (Interest Expense 54.0m / Debt 3.83b)
Taxrate = 43.30% (9.70m / 22.4m)
NOPAT = 158.5m (EBIT 279.6m * (1 - 43.30%))
Current Ratio = 2.51 (Total Current Assets 2.88b / Total Current Liabilities 1.15b)
Debt / Equity = 0.86 (Debt 3.83b / totalStockholderEquity, last quarter 4.45b)
Debt / EBITDA = 5.55 (Net Debt 3.39b / EBITDA 611.5m)
Debt / FCF = 12.51 (Net Debt 3.39b / FCF TTM 271.4m)
Total Stockholder Equity = 4.40b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.51% (Net Income -51.8m / Total Assets 10.08b)
RoE = -1.18% (Net Income TTM -51.8m / Total Stockholder Equity 4.40b)
RoCE = 3.49% (EBIT 279.6m / Capital Employed (Equity 4.40b + L.T.Debt 3.61b))
RoIC = 1.97% (NOPAT 158.5m / Invested Capital 8.04b)
WACC = 3.38% (E(1.92b)/V(5.75b) * Re(8.52%) + D(3.83b)/V(5.75b) * Rd(1.41%) * (1-Tc(0.43)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.25%
[DCF Debug] Terminal Value 79.73% ; FCFE base≈223.5m ; Y1≈272.3m ; Y5≈451.1m
Fair Price DCF = 50.97 (DCF Value 7.01b / Shares Outstanding 137.6m; 5y FCF grow 23.31% → 3.0% )
EPS Correlation: 0.16 | EPS CAGR: 2.37% | SUE: 0.18 | # QB: 0
Revenue Correlation: -83.01 | Revenue CAGR: -3.64% | SUE: -2.23 | # QB: 0

Additional Sources for PRGO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle